AGMB
AgomAb Therapeutics NV American Depositary SharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$575.87M
P/E Ratio
—
EPS
$-1.35
Beta
—
52W High
$17.45
52W Low
$9.63
50-Day MA
$13.96
200-Day MA
$13.96
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company is headquartered in Antwerp, Belgium.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-54.43M |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-7081.55 |
| Price-to-Book | 3.06 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $49.22M |
| Float | 13,300 |
| % Insiders | 0.02% |
| % Institutions | 12.31% |
Data last updated: 4/7/2026